Life Scientist > Lab Technology

Direct Capital acquires 51 per cent of New Zealand Pharmaceuticals

25 November, 2005 by Helen Schuller

New Zealand based VC Direct Capital has acquired a shareholding of 51 per cent in New Zealand Pharmaceuticals (NZP), which produces specialty chemicals for pharmaceutical and biotechnology companies.


Lack of understanding is holding back biotech: IPTA

25 November, 2005 by Helen Schuller

A survey of biotechnology patent attorneys has indicated that there is a lack of knowledge within the general population about what biotechnology encompasses and there are misconceptions regarding the patenting process.


Further extensions sought in GTG/Applera dispute

25 November, 2005 by Graeme O'Neill

Melbourne gene-test company Genetic Technologies (ASX: GTG; NASDAQ: GENE) US rival Applera Technologies have sought additional time from the US District Court of Northern California to resolve the long-running licensing dispute between the companies.


CollTech granted patent

25 November, 2005 by Ruth Beran

Perth collagen purification company CollTech (ASX:CAU) has been granted a patent by the Australian Patents Office.


Leading anti-GM figure to tour Australia

24 November, 2005 by Graeme O'Neill

Anti-GM NGO, the Australian GeneEthics Network, is hosting an Australian speaking tour by American Dr Chuck Benbrook, a prominent organic-food advocate and bete noire of genetically modified agriculture.


South Africa embracing biotech crops

24 November, 2005 by Graeme O'Neill

While commercialisation of biotech crops in Australia remains frozen by state moratoriums, South African farmers are following their peers in China, India and South American nations in enthusiastically embracing the new age of agriculture, according to a South African industry leader.


Dynamic Hearing signs agreement with House Ear Institute

23 November, 2005 by Ruth Beran

Melbourne-based biomedical company Dynamic Hearing has signed an agreement with the House Ear Institute (HEI) to develop and commercialise the US-based non-profit organisation's patented feedback cancellation technology for use in hearing aids and auditory implants.


AusBiotech, South Korea sign agreement

23 November, 2005 by Iain Scott

AusBiotech and its South Korean equivalent, the Bioindustry Association of Korea (BAK), have signed an agreement that they hope will lead to a stronger relationship between the two countries' biotech industries.


BioProspect to raise AUD$1.95m

22 November, 2005 by Helen Schuller

Brisbane natural pesticide developer BioProspect (ASX:BPO) is planning to raise AUD$1.95 million via a share placement and rights issue.


TetraQ forms strategic alliance with US company

22 November, 2005 by Ruth Beran

University of Queensland based contract research organisation TetraQ has formed a strategic alliance with Californian-based regulatory and product development consulting firm Ground Zero Pharmaceuticals (GZP).


CyGenics plans Cordlife listing in Asia

22 November, 2005 by Helen Schuller

Cell therapy company CyGenics (ASX:CYN) plans to investigate the possible listing of its tissue banking business, predominantly held under its subsidiary, CordLife, on a yet to be determined key Asian stock exchange.


Bridges, Brumby given AusBiotech honours

21 November, 2005 by Helen Schuller

The AusBiotech 2005 'Linking the Region' National Conference kicked off in Perth last night with the presentation of the chairman's Industry Medal to Peptech (ASX: PTD) executive chairman Mel Bridges and Victorian Innovation Minister John Brumby in recognition of outstanding contributions to the biotechnology industry.


International study to use Gribbles testing

21 November, 2005 by Ruth Beran

Gribbles Molecular Science (GMS), the biotechnology and molecular diagnostic division of Healthscope (ASX:HSP), has been selected to conduct genomic testing in an international collaborative study into depression.


The ASX: A haven for foreign biotech companies?

21 November, 2005 by Helen Schuller

The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports.


Australian biotech: Opportunity for growth

17 November, 2005 by Ruth Beran

Ruth Beran looks at some of the many highlights expected at the 2005 AusBiotech national conference in Perth, which kicks off on Monday.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd